Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RNAlfa Biotechnology
Hefei, Anhui Sheng, Chinarnalfa.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
RNAlfa Biotechnology is a private Chinese biotech company founded in 2021 that develops prophylactic and therapeutic vaccines using an mRNA technology platform. The company has at least two clinical trials underway targeting infectious diseases and neoplasms. Its pipeline includes multiple mRNA-based vaccines, including a respiratory syncytial virus (RSV) candidate.
- Therapeutic areas
- NephrologyOncologyInfectious Diseases
- Modalities
- mRNA vaccinemRNAProphylactic vaccineTherapeutic vaccineRNA therapy
- Industry
- Biotech
02
Partnerships
None disclosed as of April 2025
Beyond the preview
Go deeper on RNAlfa Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNAlfa Biotechnology.